CS 834

Known as: CS-834 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2003
02419972003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
The characterizations of the anhydrate (A-form), monohydrate (B1-form), and dihydrate (B2-form) of CS-834 were investigated by… (More)
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2000
2000
The in vitro activity of R-95867, the active metabolite of a new oral carbapenem, CS-834, was compared with those of DU-6859a… (More)
Is this relevant?
2000
2000
An orally bioavailable carbapenem CS-834, which is a pivaloyloxymethyl (POM) ester-type prodrug and has (R)-5-oxopyrrolidin-3… (More)
Is this relevant?
2000
2000
We determined the influence of a new quinolone, DU-6859a, and two oral carbapenems, CS-834 and L-084, on the rat and mouse caecal… (More)
  • table II
Is this relevant?
1999
1999
CS-834, a carbapenem antibiotic from Sankyo, is in phase II clinical trials for respiratory and urinary tract infections. It is… (More)
Is this relevant?
1998
1998
CS-834 is a prodrug of the carbapenem R-95867, developed by Sankyo Co., Ltd., Tokyo, Japan. To investigate the possibility that… (More)
  • figure 1
  • table II
  • figure 2
  • table III
  • table IV
Is this relevant?
1998
1998
The efficacy of CS-834, a novel oral carbapenem, was assessed by using a murine model of pneumonia caused by penicillin… (More)
Is this relevant?
1997
1997
CS-834 is a novel oral carbapenem antibiotic. This compound is an ester-type prodrug of the active metabolite R-95867. The… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
  • table 4
Is this relevant?
1997
1997
We have studied an ester prodrug of a carbapenem to develop a potent orally active beta-lactam antibiotic. A variety of 1 beta… (More)
Is this relevant?
1997
1997
CS-834, (+)-[pivaloyloxymethyl (4R,5S,6S)-6-[(R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(R)-5-oxopyrroli din-3-yl]thio]-1-azabicyclo… (More)
  • table 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?